La Jolla’s Long Road To Riquent Approval Takes Another Turn
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
La Jolla Pharmaceutical is modifying an ongoing Phase III trial evaluating its systemic lupus erythematosus candidate Riquent (abetimus) in a manner that will push back the study findings beyond the latest anticipated timeline
You may also be interested in...
Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE
Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.
Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE
Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.
La Jolla reactivates Phase III Riquent trial
La Jolla has reactivated enrollment in a Phase III trial of Riquent (abetimus sodium) in lupus renal disease under a special protocol assessment. The trial is being conducted at FDA's request based on clinical deficiencies relating to the firm's previous Phase II and Phase III trials cited in an October 2004 "approvable" letter (1Pharmaceutical Approvals Monthly November 2004, p. 13). FDA recommended another study to distinguish Riquent from placebo through an endpoint such as time to renal flare. La Jolla plans to enroll 600 patients by the second half of 2007 and has expanded the trial to include Europe and Mexico...